For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?  

Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
Agree with @Saundra S. Buys. It can take 6 months ...
Sign in or Register to read more